NO and sGC-stimulating NO donors

Handbook of Experimental Pharmacology

Volumn 191, Issue , 2009, Pages 247-276

  Megson, Ian L ^a   Miller, Mark R ^b  

^a UNIVERSITY OF THE HIGHLANDS AND ISLANDS   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Measurement; Nitric oxide; Nitrosothiols; NO donors; NO hybrids; NONOates; Organic nitrates

Indexed keywords

3 (3,4 DICHLOROPHENYL) 1,2,3,4 OXATRIAZOLE 5 IMINE; ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; ACETYLSALICYLIC ACID 4 NITROXYBUTYL ESTER; DIAZENIUMDIOLATE DERIVATIVE; DICLOFENAC; GLYCERYL TRINITRATE; GUANYLATE CYCLASE; HEME; ISOSORBIDE DINITRATE; ISOSORBIDE MONONITRATE; LINSIDOMINE; MOLSIDOMINE; NIPRADILOL; NITRATE; NITRIC OXIDE; NITRITE; NITROPRUSSIDE SODIUM; NONSTEROID ANTIINFLAMMATORY AGENT; OXYGEN; PENTAERYTHRITYL TETRANITRATE; PEROXYNITRITE; PRAVASTATIN; REACTIVE OXYGEN METABOLITE; S NITROSOTHIOL; THIOL; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; VASODILATOR AGENT; ZEOLITE; CELL RECEPTOR; NITRIC OXIDE DONOR; SOLUBLE GUANYLYL CYCLASE;

ANGINA PECTORIS; ANUS FISSURE; BRAIN DAMAGE; CARDIOVASCULAR SYSTEM; CHEMOLUMINESCENCE; DRUG COST; DRUG DOSE INCREASE; ELECTRODE; ELECTRON SPIN RESONANCE; ERECTILE DYSFUNCTION; FLUORESCENCE; GASTROINTESTINAL TOXICITY; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSIVE CRISIS; IMMUNE SYSTEM; INFLAMMATION; INFLAMMATORY DISEASE; LEUKEMIA; NEOPLASM; NERVOUS SYSTEM; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INTERACTION; PULMONARY HYPERTENSION; RESTENOSIS; REVIEW; SIGNAL TRANSDUCTION; SUBARACHNOID HEMORRHAGE; THROMBOEMBOLISM; THROMBOSIS; ANIMAL; CLINICAL TRIAL; DRUG SCREENING; METABOLISM;

ANIMALS; CARDIOVASCULAR SYSTEM; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; GUANYLATE CYCLASE; HUMANS; NITRIC OXIDE; NITRIC OXIDE DONORS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SIGNAL TRANSDUCTION;

EID: 61749095447     PISSN: 01712004     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-540-68964-5_12     Document Type: Review

References (65)

1. Abu-Soud HM, Ichimori K, Presta A, Stuehr DJ (2000). Electron transfer, oxygen binding and nitric oxide feedback inhibition in endothelial nitric oxide synthase. J Biol Chem 275: 17349-17357.
2. Al-Sa'doni H, Ferro A (2000). S-Nitrosothiols: a class of nitric oxide-donor drugs. Clin Sci (Lond) 98: 507-20.
3. Axelsson KL, Andersson RG (1983). Tolerance towards nitroglycerin, induced in vivo, is correlated to a reduced cGMP response and an alteration in cGMP turnover. Eur J Pharmacol 88: 71-9.
4. Bennett BM, McDonald BJ, Nigam R, Simon WC (1994). Biotransformation of organic nitrates and vascular smooth muscle cell function. Trends Pharmacol Sci 15: 245-9.
5. Butler AR, Megson IL (2002). Non-heme iron-nitrosyls in biology. Chem Rev 102: 1155-1165.
6. Butler AR, Megson IL, Wright PG (1998). Diffusion of nitric oxide and scavenging by blood in the vasculature. Biochim Biophys Acta 1425: 168-176.
7. Chen Z, Zhang J, Stamler JS (2002). Identification of the enzymatic mechanism of nitroglycerin bioactivation. Proc Natl Acad Sci USA 99: 8306-11.
8. Chung SJ, Fuung HL (1990). Identification of the subcellular site for nitroglycerin metabolism to nitric oxide in bovine coronary smooth muscle cells. J Pharmacol Exp Ther 253: 614-9.
9. Crane MS, Rossi AG,Megson IL (2005). A potential role for extracellular nitric oxide generation in cGMP-independent inhibition of human platelet aggregation: biochemical and pharmacological considerations. Br J Pharmacol 144: 849-859.
10. Crow JP, Beckman JS (1995). Reactions between nitric oixde, superoxide and peroxynitrite: footprints of peroxynitrite in vivo. Adv Pharmacol 34: 17-43.
11. De Belder AJ,MacAllister R, RadomskiMW, Moncada S, Vallance PJ (1994). Efects of S-nitrosoglutathione in the human forearm circulation: evidence for selective inhibition of platelet activation. Cardiovasc Res 28: 691-4.
12. De La Lande IS, Stepien JM, Philpott AC, Hughes PA, Stafford I, Horowitz JD (2004). Aldehyde dehydrogenase, nitric oxide synthase and superoxide in ex vivo nitrate tolerance in rat aorta. Eur J Pharmacol 496: 141-9.
13. Del Soldato P, Sorrentino R, Pinto A (1999). NO-aspirins: a class of new anti-inflammatory and antithrombotic agents. Trends Pharmacol Sci 20: 319-323.
14. Di Fabio J, Ji Y, Vasiliou V, Thatcher GR, Bennett BM (2003). Role of mitochondrial aldehyde dehydrogenase in nitrate tolerance. Mol Pharmacol 64: 1109-16.
15. Drago RS, Paulik FE (1960). The reaction of nitrogen(II) oxide with diethylamine. Journal of the American Chemical Society 82: 96-98.
16. Flitney FW, Megson IL, Flitney DE and Butler AR (1992). Iron sulphur cluster nitrosyls, a novel class of nitric oxide generator: mechanism of vasodilator action on rat isolated tail artery. Br J Pharmacol 107: 842-848.
17. Furchgott RF, Zawadzki JV (1980). The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980 288: 373-6.
18. Gori T, Parker JD (2002a). Nitrate tolerance: a unifying hypothesis. Circulation 106: 2510-3.
19. Gori T, Parker JD (2002b). The puzzle of nitrate tolerance: pieces smaller than we thought?. Circulation 106: 2404-8.
20. Hakim TS, Sugimori K, Camporesi EM, Anderson G (1996). Half-life of nitric oxide in aqueous solutions with and without haemoglobin. Physiol Meas 17: 267-277.
21. Han TH, Hyduke DR, VaughnMW, Fukuto JM, Liao JC (2002). Nitric oixe reaction with red blood cells and hemoglobin under heterogeneous conditions. Poc Natl Acad Sci USA 99: 7763-7768.
22. Hayward CS, Macdonald PS, Keogh AM (2001). Inhaled nitric oxide in cardiology. Expert Opin Investig Drugs 10: 1947-1956.
23. Homer KL, Wanstall JC (2002). Inhibition of rat platelet aggregation by the diazeniumdiolate nitric oxide donor MAHMA NONOate. Br J Pharmacol 137: 1071-1081.
24. Ignarro LJ (2002). After 130 years, the molecular mechanism of action of nitroglycerin is revealed. Proc Natl Acad Sci U S A 99: 7816-7.
25. Keefer LK (2005). Nitric oxide (NO)- and nitroxyl (HNO)-generating diazeniumdiolates (NONOates): emerging commercial opportunities. Curr Top Med Chem. 5: 625-36.
26. Kim D, Rybalkin SD, Pi X, Wang Y, Zhang C, Munzel T, Beavo JA, Berk BC, Yan C (2001). Upregulation of phosphodiesterase 1A1 expression is associated with the development of nitrate tolerance. Circulation 104: 2338-43.
27. Kleschyov AL, Oelze M, Daiber A, Huang Y, Mollnau H, Schulz E, Sydow K, Fichtlscherer B, Mulsch A, Munzel T (2003). Does nitric oxide mediate the vasodilator activity of nitroglycerin?. Circ Res 93: e104-12.
28. Kleschyov AL, Wenzel P, Munzel T (2007). Electron paramagnetic resonance (EPR) spin trapping of biological nitric oxide. J Chromatogr B Analyt Technol Biomed Life Sci. 851: 12-20.
29. Kojda G, Hacker A, Noack E (1998). Effects of nonintermittent treatment of rabbits with pentaerythritol tetranitrate on vascular reactivity and superoxide production. Eur J Pharmacol 355:23-31.
30. Lancaster JR (1996). Diffusion of free nitric oxide. Methods Enzymol 268: 31-50.
31. MacAllister RJ, Calver AL, Riezebos J, Collier J, Vallance P (1995). Relative potency and arteriovenous selectivity of nitrovasodilators on human blood vessels: an insight into the targeting of nitric oxide delivery. J Pharmacol Exp Ther 273: 154-60.
32. Lewis RS, Deen WM (1994). Kinetics of the reaction of nitric oxide with oxygen in aqueous solutions. Chem Res Toxicol 7: 568-574.
33. Malinsky T, Taha Z (1992). Nitric oxide release from a single cell measured by a porphyrinic-based microsensor. Nature 358: 676-678.
34. Maragos CM, Morley D, Wink DA, Dunams TM, Saavedra JE, Hoffman A, Bove AA, Isaac L, Hrabie JA, Keefer LK (1991). Complexes of.NO with nucleophiles as agents for the controlled biological release of nitric oxide. Vasorelaxant effects. J Med Chem 34: 3242-7.
35. Mayer B, Pfeiffer S, Schrammel A, Koesling D, Schmidt K, Brunner F (1998). A new pathway of nitric oxide/cyclic GMP signaling involving S-nitrosoglutathione. J Biol Chem 273: 3264-70.
36. Mollnau H, Wenzel P, Oleze M, Trieber N, Pautz A, Schulz E, Scumacher S, Reifenberg K, Stalleicken D, Scharffetter-Kochanek K, Kleinert H, Munzel Y, Daiber A (2006). Mitochondrial oxidative stress and nitrate tolerance-comparison of nitroglycerin and pentaerithrityl tetranitrate in Mn-SOD+/- mice. BMC Cardiovasc Disord 6: 44.
37. Megson IL (2002). Novel S-nitrosothiols: a means for targeted nitric oxide delivery?. Drugs Future 27: 777-784.
38. Megson IL, Webb DJ (2002). Nitric oxide donor drugs: current status and future trends. Expert Opin Investig Drugs 11: 587-601.
39. Miller MR, Grant S,Wadworth RM (2008). Selective arterial dilatation by glyceryl trinitrate is not associated with NO formation in vitro. J Vasc Res, in press.
40. Miller MR, Hanspal IS, Hadoke PW, Newby DE, Rossi AG,Webb DJ, Megson IL (2003). A novel S-nitrosothiol causes prolonged and selective inhibition of platelet adhesion at sites of vascular injury. Cardiovasc Res: 57: 853-60.
41. Miller MR, Megson IL (2007). Recent developments in nitric oxide donor drugs. Br J Pharmacol 151: 305-21.
42. Mollace V, Muscoli C, Masini E, Cuzzocrea S, Salvemini D (2005). Modulation of prostaglandin biosynthesis by nitric oxide and nitric oxide donors. Pharmacol Rev 57: 217-252.
43. Moncada S, Palmer RM, Higgs EA (1991). Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 43: 109-42.
44. Munzel T, Sayegh H, Freeman BA, Tarpey MM, Harrison DG (1995). Evidence for enhanced vascular superoxide anion production in nitrate tolerance. A novelmechanism underlying tolerance and cross-tolerance. J Clin Invest 95: 187-94.
45. Palmer RM, Ferrige AG, Moncada S (1987). Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327: 524-6.
46. Pelletier MM, Kleinbongard P, Ringwood L, Hito R, Hunter CJ, Schechter AN, Gladwin MT, Dejam A (2006). The measurement of blood and plasma nitrite by chemiluminescence: pitfalls and solutions. Free Radic Biol Med. 41: 541-8.
47. Plane F, Hurrell A, Jeremy JY, Garland CJ (1996). Evidence that potassium channels make a major contribution to SIN-1-evoked relaxation of rat isolated mesenteric artery. Br J Pharmacol 119: 1557-1562.
48. Schmidt K, DeschW, Klatt P, Kukovetz WR, Mayer B (1997). Release of nitric oxide from donors with known half-life: a mathematical model for calculating nitric oxide concentrations in aerobic solutions. Naunyn Schmiedebergs Arch Pharmacol 355: 457-62.
49. Servent D, Delaforge M, Ducrocco C, Mansuy D, Lenfant M (1989). Nitric oxide formation during microsomal hepatic denitration of glyceryl trinitrate: involvement of cytochrome P-450. Biochem Biophys Res Commun 163: 1210-6.
50. Stamler JS (1995). S-nitrosothiols and the bioregulatory actions of nitrogen oxides through reactions with thiol groups. Curr Top Microbiol Immunol 196: 19-36.
51. Stamler JS, Simon DI, Osborne JA, Mullins ME, Jaraki O, Michel T, Singel DJ, Loscalzo J (1992). S-nitrosylation of proteins with nitric oxide: synthesis and characterization of biologically active compounds. Proc Natl Acad Sci U S A 89: 444-8.
52. Suzuki N, Kojima H, Urano Y, Kikuchi K, Hirata Y, Negano T (2002). Orthogonality of calcium concentration and ability of 4,5 diaminofluoroscein to detect NO. J Biol Chem 277: 47-49.
53. Sydow K, Daiber A, Obelze M, Chen Z, August M, Wendt M, Ullrich V, Mulsch A, Schulz E, Keaney JF, Stamler JS, Munzel T (2004). Central role of mitochondrial aldehyde dehydrogenase and reactive oxygen species in nitroglycerin tolerance and cross-tolerance. J Clin Invest 113: 482-9.
54. Taylor EL, Rossi AG, Shaw CA, Dal Rio FP, Haslett C, Megson IL (2004). Human neutrophil apoptosis induced by GEA 3162 is mediated via peroxynitrite generation. Br J Pharmacol 143:179-185.
55. Thomas DD, Miranda KM, Colton CA, Citrin D, Espey MG, Wink DA (2003). Heme proteins and nitric oxide (NO): the neglected, eloquent chemistry in NO redox signaling and regulation. Antiox Redox Signal 5: 307-317.
56. Tsikas D (2007). Analysis of nitrite and nitrate in biological fluids by assays based on the Griess reaction: appraisal of the Griess reaction in the L-arginine/nitric oxide area of research. J Chromatogr B Analyt Technol Biomed Life Sci. 851: 51-70.
57. Turnbull CM, Rossi AG, Megson IL (2006). Therapeutic effects of nitric oxide-aspirin hybrid drugs. Expert Opin Ther Targets 10: 911-922.
58. Waldman SA, Murad F (1988). Biochemical mechanisms underlying vascular smooth muscle relaxation: the guanylate cyclase-cyclic GMP system. J Cardiovasc Pharmacol 12 (Suppl 5):S115-8.
59. Weber AA, Strobach H, Schror K (1993). Direct inhibition of platelet function by organic nitrates via nitric oixde formation. Eur J Pharmacol 247: 29-37.
60. Wenzel P, Hink U, Oelze M, Seeling A, Isse T, Bruns K, Steinhoff L, Brandt M, Kleschyov AL, Schulz E, Lange K, Weiner H, Lehmann J, Lackner KJ, Kawamoto T, Munzel T, Daiber A (2007). Number of nitrate groups determines reactivity and potency of organic nitrates: a proof of concept study in ALDH-2-/- mice. Br J Pharmacol 150: 526-33.
61. Wheatley PA, Butler AR, Crane MS, Fox S, Rossi AG, Megson IL, Morris RE (2006). NOreleasing zeolites and their anti-thrombotic properties. J Am Chem Soc 128: 502-509.
62. Williams DLH (1985). S-Nitrosation and the reaction of S-nitrose compounds. Chem Soc Rev 14:171-196
63. Wink DA, Nims RW, Darbyshire JF, Christodoulou D, Hanbauer I, Cox GW, Laval J, Cook JA (1994). Reaction kinetics for nitrosation of cysteine and glutathione in aerobic nitric oxide solutions at neutral pH. Insights into the fate and physiological effects of intermediates generated in the NO/O2 reaction. Chem Res Toxicol 7: 519-25.
64. Zai A, Rudd MA, Scribner AW, Loscalzo J (1999). Cell-surface protein disulfide isomerase catalyzes transnitrosation and regulates intracellular transfer of nitric oxide. J Clin Invest 103: 393-9.
65. Zhang X (2004). Real time and in vivo monitoring of nitric oxide by electrochemical sensors - from dream to reality. Frontiers in Bioscience 9: 3434-3446.